FDA Approves Sanofi Aventis's Taxotere

Drug Type: Taxotere is an anti-cancer ("antineoplastic" or "cytotoxic") chemotherapy drug.

Taxotere is classified as a "plant alkaloid," a "taxane" and an "antimicrotubule agent." (For more detail, see "How Taxotere Works" section below).

What Taxotere Is Used For:

Approved in treatment of breast cancer, non-small cell lung cancer, advanced stomach cancer, head and neck cancer and metastatic prostate cancer.
Also being investigated to treat small cell lung, ovarian, bladder, and pancreatic cancers, soft tissue sarcoma and melanoma.

Breast Cancer

TAXOTERE is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy.
TAXOTERE in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer.

Non-Small Cell Lung Cancer

TAXOTERE as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy.
TAXOTERE in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition.

Prostate Cancer

TAXOTERE in combination with prednisone is indicated for the treatment of patients with androgen independent (hormone refractory) metastatic prostate cancer.

Gastric Adenocarcinoma

TAXOTERE in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for advanced disease.

Head and Neck Cancer

TAXOTERE in combination with cisplatin and fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).

Taxotere has been approved as a treatment for subjects who have locally advanced or metastatic (spreading) breast cancer, which has progressed during anthracycline-based therapy or has relapsed during anthracycline-based adjuvant therapy. Approximately two out of three breast cancer subjects treated with chemotherapy in the United States receive anthracyclines at some point in the treatment of their disease.

Anthracycline-based chemotherapy is commonly used by oncologists as initial therapy for metastatic disease and as adjuvant chemotherapy administered in conjunction with surgery to prevent disease recurrence. In subjects with advanced disease, their cancer will eventually become resistant and stop responding to the treatment.

Taxotere is a cancer medicine that slows the growth and spread of cancer cells in the body.

Taxotere is used to treat breast cancer, lung cancer, prostate cancer, stomach cancer, and head/neck cancer.